Société Générale — M&A Activity 2020

Apr 22, 2020

National Storage Mechanism | Additional information

RNS Number : 4780K

Societe Generale SA

22 April 2020

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1)	Société Générale S.A.
Company dealt in	Allergan plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	US$0.0001 ordinary shares
Date of dealing	21/04/2020

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
Number	(%)	Number	(%)
(1) Relevant securities	2,977,854	0.90	45,208	0.01
(2) Derivatives (other than options)	0	0.00	**2,696,913	0.82
(3) Options and agreements to purchase/sell	58,500	0.02	0	0.00
Total	*7,176,929	*2.18	2,742,121	0.83

* Include the holding of 4,140,575 shares on borrow products

**The change in the holding of 841,400 shares is due to a derivative which is referenced to a basket of   securities becoming to be disclosable for the purpose of the code

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit USD (Note 5)
Purchase	300	184.84
Purchase	193	184.059378
Purchase	47	184.061702
Purchase	2,125	184.04
Purchase	970	184.04
Purchase	305	184.472951
Purchase	48	184.6
Purchase	100	184.47
Purchase	100	184.89
Purchase	100	185.84
Purchase	100	185.68
Purchase	100	184.45
Purchase	1,576	184.04
Purchase	49	184.562
Sale	99	184.35
Sale	24	184.37
Sale	315	186.088889
Sale	37	184.04
Sale	358	186.01067
Sale	77	185.55
Sale	23	185.55
Sale	100	184.47
Sale	100	184.13
Sale	2,079	185.688576
Sale	100	184.34
Sale	100	184.28
Sale	100	184.88
Sale	100	185.65
Sale	100	184.58
Sale	100	184.61
Sale	100	184.46
Sale	100	184.33
Sale	7	184.38
Sale	100	186.15
Sale	100	185.58
Sale	16	184.22
Sale	60	184.23
Sale	90	185.8
Sale	10	185.8
Sale	100	184.91
Sale	61	184.65
Sale	39	184.65
Sale	89	184.44
Sale	98	184.56
Sale	2	184.56
Sale	100	184.36
Sale	2	184.42
Sale	98	184.42
Sale	100	184.48
Sale	100	184.58
Sale	100	184.49
Sale	100	184.64
Sale	2	184.65
Sale	98	184.65
Sale	100	185.23
Sale	100	184.36
Sale	100	184.6
Sale	100	184.41
Sale	100	184.33
Sale	100	185.66
Sale	100	184.48
Sale	14	184.14
Sale	6	184.14
Sale	94	184.14
Sale	100	186.1
Sale	100	184.64
Sale	100	184.66
Sale	100	184.76
Sale	100	185.01
Sale	100	184.27
Sale	100	184.62
Sale	100	184.62
Total Purchases	6,113
Total Sales	7,098

(b)      Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit USD (Note 5)

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and 

any other person relating to the voting rights of any relevant securities under any option referred to 

on this form or relating to the voting rights or future acquisition or disposal of any relevantsecurities 

to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            Yes

Date of disclosure	22/04/2020
Contact name	Société Générale - Disclosure team
Telephone number	+33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

Ap23

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL 

ACT, 1997, TAKEOVER RULES, 2013

DETAILS OF OPEN POSITIONS

(This form should be attached to Form 8.1(a) & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

OPEN POSITIONS (Note 1)

Product name, e.g. call option	Written, or purchased	Number of relevant securities to which the option or derivative relates	Exercise price (Note 2)	Type, e.g. American, European etc.	Expiry date
Listed Put Option	Sale	40,000	175	American options	15/01/2021
Listed Put Option	Sale	18,500	190	American options	15/01/2021

Notes

1.          Where there are open option positions or open derivative positions (except for CFDs), full details should

be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

2.          For all prices and other monetary amounts, the currency must be stated.

For full details of disclosure requirements, see Rule 8 of the 

Rules. If in doubt, consult the Panel.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

ISEDLLBLBZLLBBK